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Summary 
We have detected,  in sera of normal human immunodeficiency virus (HIV)-free subjects, IgM 
antibodies reactive with the Tat protein of HIV in significant titers and at very high frequency, 
and, in HIV-positive sera, progressively lower titers as HIV pathogenesis ensues. Epitope analysis 
indicates that the Tat-reactive antibodies of both HIV-negative and HIV-positive sera are homolo- 
gous,  suggesting,  therefore,  that  their decline in HIV-positive sera may represent  attrition  of 
a host defense factor.  The identified epitope displays  minimal  homology with that  previously 
defined for another set of IgM antibodies shown to be present in normal sera, deficient in HIV- 
positive sera, and postulated to be natural antibodies. We propose that the Tat-reactive  antibodies, 
as well, are a set of natural  antibodies and that  the normal  humoral  immune  system includes 
a repertoire of antibodies,  nonimmunogenic  in origin,  that contribute to immune homeostasis 
and,  consequently,  to host resistance to HIV pathogenesis. 
T 
he progression of HIV pathogenesis from infection to 
AIDS is highly variable in rate and in pathophysiolog- 
ical manifestations.  While some variability is attributable to 
genetic variance of the virus,  there is great likelihood that 
host factors, some possibly not yet identified, are significant 
determinants  of, for example, duration  of latency between 
infection and morbidity.  We have directed our attention  to 
one arm of the humoral immune system in which such factors 
might  reside:  the natural  antibody repertoire. 
Among the various functions  or raisons d'etre proposed 
for natural antibodies is that they may constitute a "first line 
of defense" against invading infectious agents (1). In consider- 
ation of that putative function of natural antibodies as a mech- 
anism of host defense against HIV, we have previously provided 
evidence that certain subsets of natural antibodies are present 
in sera of healthy HIV-negative subjects and deficient or ab- 
sent in sera of patients diagnosed with AIDS (2, 3). In the 
more recent study (3) the antigenic specificity of the subset 
of natural antibodies was defined, and decline of those anti- 
bodies in HIV-positive sera was shown to be related to the 
imminence of AIDS.  The antigens with which the subsets 
of natural antibodies were detected were those derived from 
sperm surface components (2, 4) and from protamine, a sperm- 
unique nuclear protein (3, 5). In this study we have identified 
what appears to be another set of natural antibodies indigenous 
to normal sera, depleted in the course of HIV infection and, 
of particular  significance, specifically reactive with Tat, a regula- 
tory transactivation protein of HIV (6). Tat has been shown 
in vitro to activate viral replication (7, 8), to be exocytosed 
(9), and to adhere to various classes of cells (10). If those do 
indeed reflect events in vivo, the presence,  in the early postin- 
fection period, of Tat-reactive antibodies in the plasma may 
provide a mode of inhibition  of Tat  activity, impedance of 
stimulation  of HIV replication,  and,  consequently,  main- 
tenance of latency or asymptomatic  status. 
Materials and Methods 
Sera.  HIV-positive sera were collected from blood specimens 
of individuals at risk for AIDS during the period 1983-1990, and 
stored in small aliquots at  -60~  Diagnosis at specimen collec- 
tion and at subsequent clinical examinations allowed the sera to 
be assigned to three classes: (a) AIDS, (b) AIDS within 1 yr, and 
(c) asymptomatic or state of latency for >1 yr. The HIV-negative 
sera were selected randomly from a store of 200 specimens, including 
donations  from  laboratory  personnel  and discards from clinical 
laboratories identified by age, sex, and "no clinical findings:' Those 
specimens also were collected throughout the period 1983-1990, 
and stored at  -60~  HIV positivity for all sera was determined 
by immunotransfer as described (3) or by report from certified clinical 
laboratories. 
Antigens.  Recombinant  HIV Tat protein  (complete, residues 
1-86) representing the BH10, HxP2 isolates (11, 12) and HIV Nef 
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in baculovirus, were  obtained from American Biotechnologies  Inc. 
(Cambridge, MA). Synthetic truncated Tat was a gift, prepared 
as described (13). 11 overlapping dodecapeptides of Tat, including 
residues 1-82, constructed from the sequence described (14), were 
prepared by Multiple Peptide Systems (San Diego, CA).  pp,  a 
dodecapeptide representing residues 33-44 of human protamine 2b 
(15, 16) was prepared by The Rockefeller University Protein Se- 
quencing Service. All peptides were synthesized by the method of 
Merrifield (17), and amino acid content of each was verified  by the 
Mass Spectrometric Biotechnology Resource of The Rockefeller 
University. 
ELISA.  IgM reactivity of each serum with Tat, peptides of 
Tat, gp120, p24, and Nef was determined by ELISA as described 
(3, 5, 18). Briefly, 50/4 of 10/~g antigen/ml PBS was placed in 
each well (96-well microtiter plates; Dynatech Laboratories, Inc., 
Alexandria, VA), incubated at room temperature for 3 h, blocked 
with 3% BSA overnight at 5~  then with 1% preimmune rabbit 
serum for I h (blocking with preimmune rabbit serum eliminated 
background attributable to the second antibody). 50 #1 of the test 
serum (1:100) was added to the wells, incubated for 2 h, followed 
by 50 #1 of the peroxidase-labeled second antibody: IgG isolated 
from serum of a rabbit immunized with purified total IgM from 
pooled normal sera, for 1.5 h. 50/~1 substrate, orthophenylene dia- 
mine (0.2 mg/ml) was added to each well, allowed to incubate for 
30 min at room temperature, and the reaction stopped by the addi- 
tion of 50 #1 2.5 N H2SO4. After removal of each reagent, the 
wells were washed 20 times with 0.05% Tween 20/PBS. The OD 
at 490 nm, of each well, was read in a microplate reader (MR 700; 
Dynatech Laboratories,  Inc.). All appropriate  controls were included 
and caveats for correction for background and other methodologic 
sources of error in the ELISA were observed (19). Each plate in- 
cluded both HIV-positive  and HIV-negative  sera, each reaction was 
carried out in duplicate, and each serum was assayed two to five 
times. Throughout the study, a single normal serum was assayed 
for reactivity with HIV Tat 48 times with a mean corrected OD 
value of 0.50 for 1:100 dilution of serum with 10 #g/ml of Tat 
(SEM  =  1.2). ELISA with pp as antigen and calculation of the 
proportionate titer of the low affinity subset of pp-reactive IgM, 
designated as the natural antibody subset, was carried out as de- 
scribed (3). 
Ek'thiothreitol(DTT) Treatment  of  Peptides.  To determine whether 
the epitope of Tat with which the serum IgM antibodies are reac- 
tive is represented by the linear sequence of Tat peptide no. 4 or 
by a conformation-dependent  structure resulting from S-S bonding 
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Figure 1.  Titers,  measured  by 
ELISA and expressed as OD of 
IgM antibodies  reactive  with HIV 
Tat in sera of: (.4) clinically  nor- 
mal, HIV-negative  males  (n ~ 41) 
and females (n = 25); (/3) HIV- 
positive (I) diagnosed  with AIDS 
at specimen  collection  (n = 24); 
(2) diagnosed  with AIDS within 
I yr from specimen  collection  (n 
= 10); (3) asymptomatic  or state 
of latency for >1 yr (n  =  26). 
of the cysteinyl residues, assay of the reactivity of HIV-negative 
and HIV-positive sera with Tat peptide no. 4 was carried out by 
the conventional procedure with the peptide in PBS and, in par- 
allel, with Tat peptide no. 4 in 10 mM DTT/PBS. The same proce- 
dure was carried out for serum IgM reactivity  with pp (see Table 2). 
Immunotransfers of  lgM and lgG Reactivity.  Immunotransfers of 
representative sera with each of the HIV proteins was carried out 
as follows. A wide PAGE of each HIV protein (gp120, p24, Nef, 
Tat, synthetic truncated Tat) was prepared and transferred to Im- 
mobilon P membrane. A pair of 2-mm strips, representing 1.5 #g 
protein each, were incubated in 1:100 dilution of serum for 2 h 
at room temperature. The strips were washed with PBS/Tween 
20, then one of each pair was incubated in peroxidase-labeled  rabbit 
IgG anti-human IgM and the other in anti-human IgG, washed, 
and incubated  in substrate, 3-amino-9-ethyl  carbazole, for 1 h. Reac- 
tion was stopped by washing (HzO) and air drying. 
Results 
Assay of Sera for IgM Reactivity with Tat.  Sera of 66 HIV- 
negative and 60 HIV-positive adult males and females, none 
of  whom had received antiviral or immune-corrective therapy, 
were assayed for IgM antibodies reactive with HIV Tat. As 
shown (Fig.  1 A), of the HIV-negative sera from clinically 
normal subjects,  100% of the female and 95% of the male 
sera had titers within a circumscribed range.  For the HIV- 
positive sera (Fig. 1 B), 66% of those diagnosed with AIDS 
(class 1), 40% of those from patients for whom a diagnosis 
of AIDS was entered within 1 yr (class 2), and 35% of those 
who remained AIDS free for >1 yr (class 3) had titers below 
that range. These data suggest that progression to AIDS is 
accompanied by a decline in HIV-positive sera of a constant 
component of normal sera: a set of IgM antibodies reactive 
with HIV Tat protein. 
HIV-negative Sera Are Not Reactive with HIV Proteins Other 
than Tat.  Further creditation for the specificity and unique 
occurrence of the Tat-reactive antibodies (Fig. 1) was sought 
by inspecting the reactivity of a representative  group of sera 
with other HIV proteins as well as Tat, and by utilizing an- 
other method of immunochemical analysis (Fig. 2). The HIV 
proteins selected for this comparison were the structural pro- 
teins gp120 and p24 and, in addition to Tat, another regula- 
tory protein, Nef. The most frequently used criterion for HIV 
positivity is that of reactivity with the structural proteins. 
There is weU-accepted evidence that antibodies to the enve- 
lope protein gp120 appear soon after infection and are present 
at all subsequent stages (20), while antibodies to the gag pro- 
tein, p24, decline as disease progresses  (21). The role of the 
Nef protein in HIV replication or expression in vitro has not 
been clearly defined (22).  Detection of antibodies to HIV 
Nef in sera of patients at all stages of HIV infection has been 
reported (for review, see reference 23); that prevalence, how- 
ever, has been questioned (for review,  see reference  24). 
Detection of Tat-reactive ~IgG antibodies in some HIV- 
positive sera has been reported and interpreted as evidence 
of immune response  to the viral protein; no reactivity with 
Tat by IgG of HIV-negative sera was observed (25, 26). Our 
own interest has centered on IgM antibodies as the principle 
class identified as natural antibodies. However, to correlate 
1248  HIV Tat-reactive Antibodies in Normal HIV-free Sera Figure 2.  (+4) Immunotransfers 
of IgM and IgG reactivity of repre- 
sentative sera from the classes de- 
scribed in Fig. 1, with HIV struc- 
tural  proteins  gp120, p24,  the 
regulatory  protein  Nef,  the  re- 
combinant Tat, and a synthetic trun- 
cated Tat. (Lane a) Molecular mass 
markers on 10% polyacrylamide  gel: 
200, 130, 92, 66, and 43 kD; (lane 
b) molecular mass markers on 12% 
gel: 92, 66, 43, 30, 20, and 14.4 kD. 
For each of the following  lanes, the 
left hand member of the pair is IgM 
and the right hand member is IgG: 
(lane c) gp120, 10% gel; (lanes d-g) 
12% gel; (lane d) p24; (lane e) Nef; 
(lane f) recombinant Tat; (lane g) 
synthetic Tat (residues 1-68).  Sera 
nos. 1 and 2 are HIV negative; sera 
nos. 3 and 4 are from class 1, AIDS; 
serum no. 5 is from class 3, state of 
latency. The strong band at ~240 
kD on the IgG member of lane c, 
sera nos. 3, 4, and 5, and the weak 
band at 45 kD for sera 3 and 5 were 
proven, by reactivity with a mAb 
to gp120, to be, respectively, a gp120-derived dimer and peptide (not shown). (B) ELISA of IgM reactivity of the same sera presented in A, paralleling 
and supporting the inferences of the data for the reactions displayed in A. 1:100 dilution of each serum was assayed for IgM reactivity with 2, 5, 
and 10/zg/ml of each protein,  and the corrected OD values were plotted  (18). x, Tat; A, gp120; II, p24;  O, Nef. 
the data of this report with those previously published (25, 
26), immunotransfers of IgG reactivity of each serum with 
each HIV protein were included (Fig. 2 A). As shown (Fig. 
2 A), the IgG reactivity of each serum with each of that panel 
of HIV proteins is in accord with the referred published data. 
Sera nos. 1 and 2 (HIV negative) show no reactivity with 
gp120; sera nos. 3, 4, and 5 (HIV positive) show weak IgM 
and strong IgG reactivity with gp120. Only serum no. 5 (state 
of latency) displays reactivity,  IgM and IgG, with p24. The 
three HIV-positive sera (nos.  3,  4,  and 5) show IgG reac- 
tivity with Nef, and sera nos. 4 and 5 show IgM reactivity, 
as well. In accordance with the data of Fig. 1, the HIV-negative 
sera (nos. 1 and 2) show high IgM reactivity with Tat, while 
the two AIDS sera (nos. 3 and 4) show no discernible reac- 
tivity,  and  the  HIV-positive,  state-of-latency  serum show 
moderate IgM reactivity with Tat. Each display of IgM reac- 
tivity with Tat is accompanied by display of IgG reactivity, 
although the relative densities of the IgM and IgG bands differ 
for the HIV-negative and HIV-positive sera. Reactivity with 
the truncated synthetic Tat (Fig.  2,  lane g) is comparable, 
for each serum, with that with the recombinant Tat (lane 
f), thus assuring that the observed reactivity is not attributable 
to autogenous proteins of the bacterial vector. The IgM reac- 
tivities displayed for each serum by the ELISA (Fig. 2 B) are 
markedly  consistent  with  those  detected  by  the  im- 
munotransfers (Fig.  2 A). 
Assay of Sera for Natural IgM Antibodies Reactive with pp. 
This probe for natural antibodies reactive with HIV Tat was 
suggested by the linear sequence of the epitope for the set 
of protamine-reactive IgM antibodies previously character- 
ized (3, 5). That epitope was identified as one with a concen- 
tration of four arginyl residues,  consisting of a triplet plus 
one within a six-residue sequence. Therefore, the identification 
of an arginine-rich sequence in HIV Tat (27) was provocative 
and suggested that the same set of natural antibodies might 
display reactivity with Tat.  In that regard, each of the sera 
assayed for Tat-reactive IgM antibodies (Fig.  1) was assayed 
A  B 











￿9 -  !: 
..  ::' 
., 
~i:"  :  ;. 
. ....  ..  ::. 
+.  ~176 
:..:  ..  ... 
+. 
ct  9  ""  ~  " 
1  2  3 
Figure 3.  Titers  of the  same 
sera as those of Fig. 1, measured 
by ELISA and expressed as the de- 
rived OD representing the subset 
of low aflfinity IgM antibodies, 
designated as natural antibodies 
(3),  reactive with pp,  a peptide 
(residues 33-44) of human prota- 
mine 2b (5). The ELISA protocol 
and  formula  for  deriving  the 
proportional titer of protamine- 
reactive IgM t~presenting the low 
a~nity subset and designated as 
natural antibodies, distinct from 
a subset of high affinity IgM an- 
tibodies attributable to immuno- 
induction by protamine, have  been 
described (3). (A) With the lower 
limit of the normal range of titers 
designated  as .10, 11% of  the HIV- 
negative sera show titers below that limit. (B) Of the HIV-positive sera, 
96% of class 1 (AIDS),  80% of class 2 (AIDS within 1 yr), and 71% 
of class 3 (state of latency) show titers below the designated lower limit 
of normal range. 
1249  Rodman et al. also for titer of natural  IgM antibodies  reactive with a pep- 
tide, pp (Fig. 3), representing  a 12-residue sequence ofprota- 
mine and  including  one copy of the deduced epitope (5). 
The protocol and formula for deriving the proportionate 
titer of protamine-reactive  IgM antibodies  comprising the 
low affinity subset and designated as natural antibodies, dis- 
tinct from a subset of high affinity IgM antibodies attributable 
to immunoinduction by protamine of sperm,  have been de- 
scribed (3). By application  of that formula,  the titer of nat- 
ural antibodies reactive with pp was derived for each serum 
(Fig. 3). As shown, the general distributions of pp-reactive 
(Fig. 3) and Tat-reactive (Fig. 1) natural  IgM antibodies  in 
the various groups of sera are similar. With the lower limit 
of the normal range designated as 0.10, only 11% of the HIV- 
negative  sera show titers  of reactivity  with pp below that 
limit (Fig. 3 A), while,  of the HIV-positive sera (Fig. 3 B), 
96% of those from patients  diagnosed with AIDS (class 1), 
80% of those from patients  diagnosed  with AIDS within 
1 yr (class 2), and 71% from those who remained AIDS-free 
for >1 yr (class 3) show titers  below the normal range. 
Probe for  the Epitope of Tat Recognized by Serum IgM. 
Identification  of the epitope was sought by assay of sera of 
each of the two groups,  HIV negative and HIV positive, for 
IgM reactivity against a series of overlapping peptides of Tat, 
pp, and the total Tat (Table 1). The apparent  homology of 
Table  1.  Ei~itope Specificity for HIV  Tat-reactive IgM Antibodies 
arginine distribution in pp and Tat peptide no. 8 engendered 
the expectation  that both would be recognized by the same 
set of IgM antibodies.  It was particularly  surprising,  there- 
fore,  to observe no reactivity  by any of the sera with the 
arginine-rich  Tat peptide no. 8, nor with any of the Tat pep- 
tides other than peptide no.  4 (Table 1). All  sera, of both 
groups, were reactive to varying degree with Tat peptide no. 
4, with pp, and with total Tat. The limited homology be- 
tween the two dodecapeptides, Tat peptide no. 4 and pp, sug- 
gests  that  this  study has revealed two sets of natural  anti- 
bodies: one reactive with an epitope characteristic of Tat peptide 
no.  4,  and another with an epitope indigenous  to pp, but 
not present  in Tat peptide no. 4 nor in any linear sequence 
of Tat. 
The assays of serum IgM reactivity with Tat and with the 
peptides  of Tat displayed in Table 1 were carried out in the 
conventional protocol, which included solution of Ag in PBS. 
The presence of five cysteinyl residues in Tat peptide no. 4 
suggested  that  the epitope might  be dependent upon S-S 
bond-induced conformation. Therefore,  HIV-negative  and 
HIV-positive sera of each class were assayed  for reactivity with 
Tat peptide no. 4 in 10 mM DTT and compared  with the 
reactivity  of peptide no.  4  in  conventional  (nonreducing) 
medium (Table 2). The sera were assayed also for compara- 
tive reactivity  of pp in conventional  and reducing  solution. 
No.  Residues  Tat peptides 
OD 490 nm 
HIV-neg  HIV-pos 
Serum:  1  2  3  4  5  6 
1  1-12  Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys 
2  8-19  Leu Glu Pro Trp Lys His Pro Gly Set Gln Pro Lys 
3  15-26  Gly Set Gln Pro Lys Thr Ala Cys Thr Ash Cys Tyr 
4  22-33  Cys Thr Asn Cys Tyr Cys Lys Lys Cys Cys Phe His 
5  29-40  Lys Cys Cys Phe His Cys Gln Val Cys Phe Ile Thr 
6  36-47  Val Cys Phe Ile Thr Lys Ala Leu Gly Ile Ser Tyr 
7  43-54  Leu Gly Ile Ser Tyr Gly Arg Lys Lys Arg Arg Gln 
8  50-61  Lys Lys Arg Arg Gln Arg Arg Arg Pro Pro Gln Gly 
9  57-68  Arg Pro Pro Gln Gly Ser Gln Thr  His Gln Val Set 
10  64-75  Thr  His Gln Val Ser Leu Ser Lys Gln Pro Thr Ser 
11  71-82  Lys Gin Pro Thr Set Gln Ser Arg Gly Asp Pro Thr 
pp  Ser  Cys Arg  His  Arg Arg  Arg  His Arg Arg Gly Cys 
Tat  (total)  1-86 
0.26 0.31 0.13 0.11 0.21 0.21 
0.24  0.39  0.22  0.26  0.18  0.20 
0.35 0.49 0.33 0.09 0.17 0.20 
HIV-negative sera (nos.  1-3) and HIV-positive  sera (nos. 4-6) were assayed for lgM reactivity with a series of overlapping  12 residue peptides of 
Tat, pp, a 12-residue peptide of protamine (5),  and with the total recombinant Tat protein. Sera nos. 4 and 5 were class 1,  AIDS and serum 6 
was class 3, state of latency (Fig.  1 B). 50/zl of 1:100 dilution of serum was tested against 50/xl of 10/~g/ml of each peptide in accordance with 
the ELISA protocol,  and the OD for each serum/peptide reactivity was corrected for background (18). Reactivity by all sera was displayed with 
Tat protein, with pp, and with Tat peptide 4, but with no other Tat peptide. Despite the apparent homology of arginine distribution in Tat peptide 
8 and pp, no reactivity with peptide 8 was displayed by any of the sera tested.  Levels of reactivity with pp were consistent with those previously 
determined for protamine and other protamine-derived  peptides (3) and with the data of Fig. 3.  The reactivity of each serum with the complete 
Tat protein was in accordance with the data of Fig.  1. 
1250  HIV Tat-reactive Antibodies in Normal HIV-free Sera Table  2.  Decline in Serum IgM Reactivity with Tat 
Peptide No.  4 and pp, after DTT Treatment of Peptides 
Sera  Antigen  n  Percent decline (M) 
HIV-neg  Tat pep. no. 4  18  92.6 
HIV-pos.  Tat pep. no. 4  17  93.5 
HIV-neg.  pp  18  25.8 
HIV-pos.  pp  14  28.5 
The data of Table 2 show that the reactivity of the sera with 
Tat peptide no. 4 is virtually eliminated when the antigen 
is in the reduced state, thus establishing that the epitope on 
Tat peptide no. 4 is conformation dependent. With regard 
to pp, the presence of DTT resulted in only moderate decline 
in reactivity,  suggesting that the epitope of pp recognized 
by serum IgM has little dependence upon the conformation 
induced by S-S bond between the two cysteinyl residues, and 
confirming the previous observations that the repetitive epi- 
tope of protamine is that of a triplet plus one of arginine 
in a linear six-residue piece (5). The demonstration of the 
difference in response to DTT treatment by the two pep- 
tides, Tat no. 4 and pp, serves, fortuitously, to validate the 
discriminatory capability of that treatment for detecting S-S 
bond-dependent conformational epitopes and supports the 
interpretation that the epitope on HIV Tat is a conforma- 
tional one that is recognized by both HIV-positive and HIV- 
negative sera. 
Discussion 
The primary observation reported here is provocative:  all 
sera of a randomly selected group of clinically normal, HIV- 
negative individuals contain a measurable titer of IgM anti- 
bodies reactive with the protein product of the HIV tat gene. 
Within presently accepted concepts of immunology, those 
antibodies are attributable to: (a) immunologic induction by 
an exceedingly ubiquitous exogenous antigen homologous 
with the region of Tat with which those antibodies are reac- 
tive; or (b) nonimmunogenic origin, therefore natural anti- 
bodies. Since the observations reported here also suggest that 
depletion of those antibodies occurs concomitantly with the 
progression, after HIV infection, to AIDS, we have accorded 
greater credibility to the latter. 
Among the characteristics attributed to natural antibodies 
since their existence was postulated byJeme in 1955 (28) are: 
preimmune origin or nonimmunogenic induction (1, 3, 5) 
with adaptability to antigenic demand (29,  30),  capability 
of binding to autogenous or exogenous antigens (31), poly- 
or monoreactivity (30, 31), IgM of low binding affinity (3, 
32, 33) secretion by CD5 B cells (1, 33-36), participation 
in idiotypic networks with a role in maintenance of homeo- 
stasis (37-43), association with autoimmunity (44, 45), and 
first line of defense against invading infectious agents (1). The 
latter, in its most simplistic interpretation, presents a frame- 
work into which the data of this report may fit.  That in- 
terpretation would allow that the Tat-reactive antibodies are 
a component of the neonatal or preimmune repertoire,  are 
retained or replenished at significant titer throughout life unless 
the B cell lines of their origin are demolished (by disease, 
autoimmunity?), and, upon encounter with a foreign antigen 
that they recognize, establish an attack similar to that of neu- 
tralizing antibodies, maintain that attack for a host-variable 
limited period, then decline. 
On the other hand, it should be noted that the distribu- 
tion of titers of Tat-reactive IgM antibodies in the various 
classes of HIV-positive sera allows an alternative to that in- 
terpretation: in the postinfection pre-AIDS period (class 3), 
an immune response to Tat may occur, resulting in a set of 
induced Tat-reactive antibodies, possibly unrelated to the nat- 
ural Tat-reactive antibodies. However, the implication of the 
data of Table 2, that the epitope for the Tat-reactive antibodies 
of HIV-positive sera is identical with or closely related  to 
that of the HIV-negative sera, while not precluding that pos- 
sibility, does not strongly support it. Another possible con- 
sideration, and one that is consistent with the epitope study 
(Tables 1 and 2), is that the presence of the Tat-reactive anti- 
bodies in HIV-positive sera might be consonant with the hy- 
pothesis that the immune response to HIV is under idiotypic 
network control (46-48) with the natural anti-Tat antibodies 
functioning as Abl. The possibility that the natural antiprota- 
mine antibodies, represented in this study as the pp-reactive 
set, may, in homosexual practice, be a factor in perturbation 
of immunologic  equilibria such as idiotypic networks has been 
discussed in the context of the molecular, cytologic, and on- 
togenetic characteristics  of protamine, a sperm-unique nu- 
clear protein that is synthesized de novo in the testes of the 
postpuberal male.  (2, 3). 
Thus, whatever the nature of the subsequent humoral re- 
sponse, the data of this report suggest that the host's innate 
store of natural antibodies may provide the first retardation 
of the progression of HIV pathogenesis. Might that store 
be replenished? Could that replenishment be a basis for the 
slower progression to AIDS in HIV-infected hemophiliacs 
(49),  for improvement in immune status of AIDS patients 
who have received plasma from "healthy HIV-infected indi- 
viduals" (50), or for the HIV-infected pediatric patients who 
have received intravenous immunoglobulins obtained from 
the "blood of normal, healthy donors" (51) and have benefitted 
(52)? 
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